KR960040370A - Alcohol Disorder Prevention and Treatment Composition - Google Patents

Alcohol Disorder Prevention and Treatment Composition Download PDF

Info

Publication number
KR960040370A
KR960040370A KR1019950010640A KR19950010640A KR960040370A KR 960040370 A KR960040370 A KR 960040370A KR 1019950010640 A KR1019950010640 A KR 1019950010640A KR 19950010640 A KR19950010640 A KR 19950010640A KR 960040370 A KR960040370 A KR 960040370A
Authority
KR
South Korea
Prior art keywords
vitamin
composition
alcohol
composition according
golden extract
Prior art date
Application number
KR1019950010640A
Other languages
Korean (ko)
Inventor
강상모
Original Assignee
강상모
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 강상모 filed Critical 강상모
Priority to KR1019950010640A priority Critical patent/KR960040370A/en
Publication of KR960040370A publication Critical patent/KR960040370A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 황금 (黃芩 Scutellaria baicalensis) 추출물(바이칼린 (baicalin)을 비롯한 후라본배당체들(flavonoid glycosides)을 포함한다)을 함유함을 특징으로 하는 알콜장해 예방 및 치료제조성물에 관한 것이다. 본 발명의 조성물은 이외에도 바람직한 것으로 비타민B 및/혹은 비타민C를 함유할 수 있다. 본 발명에 따른 조성물은 한약제인 황금과 비타민을 사용하기 때문에 기존의 진통제에서 야기 되었던 각종 부작용없이 효과적으로 알콜장해를 예방 및 치료할 수 있다. 또한 술제조시 이를 이용하므로 알콜장해를 예방할 수 있다.The present invention relates to a composition for the prevention and treatment of alcohol disorders, which comprises golden (Scutellaria baicalensis) extract (including flavonoid glycosides including baicalin). The composition of the present invention may further contain vitamin B and / or vitamin C as preferred. Since the composition according to the present invention uses the gold and vitamin Chinese medicine, it is possible to effectively prevent and treat alcohol disorders without various side effects caused by conventional pain medications. In addition, alcohol use can be prevented by using this during manufacturing.

Description

알콜 장해 예방 및 치료제 조성물Alcohol Disorder Prevention and Treatment Composition

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

제1도는 시간의 경과에 따른 두통의 강도변화 및 진행상태를 개략적으로 나타낸 그래프, 제2도는 알콜성두통시 루이코트리엔 Ｂ4의 변화그래프, 제3도는 급성알콜투여에 의한 혈청중LDH의 변화, 제4도는 급성알콜투여에 의한 혈청중 GOD, GPT의 변화.A first graph showing an intensity variation and the progress of the headache with the lapse of the turn time schematically, a second turning alcoholic headache when Louis coat Li yen change of B 4 graph, the first 3 LDH in serum by acute alcoholic administration turn Change, FIG. 4 shows changes in GOD and GPT in serum by acute alcohol administration.

Claims (12)

황금 (黃芩 Scutellaria baicalensis) 추출물 (바이칼린 (baicalin)을 비롯한 후라본 배당체들(flavonoid glycosides)을 포함한다)을 함유함을 특징으로 하는 알콜 장해 예방 및 치료제조성물.A composition for the prevention and treatment of alcohol disorders, which comprises golden extract of Scutellaria baicalensis (including flavonoid glycosides including baicalin). 제1항에 있어서, 추가로 비타민 Ｂ 및/혹은 비타민Ｃ(비타민Ｃ 유도체 포함한다)를 함유함을 특징으로 하는 조성물.The composition of claim 1, which further contains vitamin X and / or vitamin C (including vitamin C derivatives). 제1항에 있어서, 황금 추출물이 성인체중 ㎏당 0.1㎎내지 80㎎을 음주전후 혹은 중간에 복용하도록 제형화됨을 특징으로 하는 조성물.The composition of claim 1, wherein the golden extract is formulated to take 0.1 mg to 80 mg per kg body weight before or after drinking. 제1항에 있어서, 비타민 Ｂ 및/혹은 비타민Ｃ (비타민Ｃ 유도체 포함한다)를 함유함을 특징으로 하는 조성물.A composition according to claim 1, which contains vitamin X and / or vitamin C (including vitamin C derivatives). 제4항에 있어서, 황금추출물, 비타민Ｂ, 비타민Ｃ를 중량기준으로 1∼800:1∼200:10∼1000의 비로 함유함을 특징으로 하는 조성물.The composition according to claim 4, which contains golden extract, vitamin X and vitamin C in a ratio of 1 to 800: 1 to 200: 10 to 1000 by weight. 제5항에서, 황금추출물, 비타민B를 중량기준으로 100∼300:40∼120:100∼500의 비로 함유함을 특징으로 하는 조성물.The composition according to claim 5, wherein the golden extract contains vitamin B in a ratio of 100 to 300: 40 to 120: 100 to 500 by weight. 제1내지 제6항중의 어느 하나에 있어서, 추가로 적어도 하나의 약제학적으로 허용되는 담체를 함유함을 특징으로 하는 조성물.The composition according to any one of claims 1 to 6, which further contains at least one pharmaceutically acceptable carrier. 제8항에 있어서, 정제 연질캅셀제 또는 액제로 제형화됨을 특징으로 하는 조성물.The composition according to claim 8, which is formulated as a tablet soft capsule or liquid. 술을 제조함에 있어서, 알콜장해 보호를 할 수 있는 황금 추출물(바이칼린 (baicalin)을 비롯한 후라본 배당체들(flavonoid glycosides)을 포함한다)을 재료로 이용하는 방법.In the manufacture of alcohol, using a golden extract (including flavonoid glycosides including baicalin) as a material that can protect against alcohol disorders. 제9항에 있어서, 추가로 비타민 Ｂ 및/혹은 비타민Ｃ(비타민Ｃ유도체 포함한다)를 함유함을 특징으로 하는 조성물.10. A composition according to claim 9, further comprising vitamin X and / or vitamin C (including vitamin C derivatives). 제9 및 제10항에 있어서, 알콜, 황금 추출물, 비타민Ｂ, 비타민Ｃ를 중량기준으로 10×1000-250×1000:10-1000:1-300:1-1000의 비로 함유함을 특징으로 하는 조성물.The method according to claim 9 or 10, characterized in that it contains alcohol, golden extract, vitamin Ｂ, vitamin C in a ratio of 10 × 1000-250 × 1000: 10-1000: 1-300: 1-1000 by weight. Composition. 제11항에 있어서, 알콜, 황금 추출물, 비타민Ｂ, 비타민Ｃ를 중량기준으로 50×1000-180×1000 : 50-500:10-150:10-300의 비로 함유함을 특징으로 하는 조성물.The composition according to claim 11, wherein the composition contains alcohol, golden extract, vitamin X and vitamin C in a ratio of 50 × 1000-180 × 1000: 50-500: 10-150: 10-300 by weight. ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.※ Note: This is to be disclosed by the original application.
KR1019950010640A 1995-05-01 1995-05-01 Alcohol Disorder Prevention and Treatment Composition KR960040370A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019950010640A KR960040370A (en) 1995-05-01 1995-05-01 Alcohol Disorder Prevention and Treatment Composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019950010640A KR960040370A (en) 1995-05-01 1995-05-01 Alcohol Disorder Prevention and Treatment Composition

Publications (1)

Publication Number Publication Date
KR960040370A true KR960040370A (en) 1996-12-17

Family

ID=66523683

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950010640A KR960040370A (en) 1995-05-01 1995-05-01 Alcohol Disorder Prevention and Treatment Composition

Country Status (1)

Country Link
KR (1) KR960040370A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8247007B2 (en) 2006-10-12 2012-08-21 Unigen, Inc. Composition for treating atopic dermatitis comprising extracts of bamboo and Scutellaria
US9622964B2 (en) 2003-04-04 2017-04-18 Unigen, Inc. Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care
US9655940B2 (en) 2002-04-30 2017-05-23 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9655940B2 (en) 2002-04-30 2017-05-23 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent
US9849152B2 (en) 2002-04-30 2017-12-26 Unigen, Inc. Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent
US9622964B2 (en) 2003-04-04 2017-04-18 Unigen, Inc. Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care
US8247007B2 (en) 2006-10-12 2012-08-21 Unigen, Inc. Composition for treating atopic dermatitis comprising extracts of bamboo and Scutellaria
US8771761B2 (en) 2006-10-12 2014-07-08 Unigen, Inc. Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria
US9623068B2 (en) 2006-10-12 2017-04-18 Unigen, Inc. Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria

Similar Documents

Publication Publication Date Title
Sierpina et al. Ginkgo biloba
CA2154601A1 (en) Formulations containing coumarins and the use thereof in the pharmaceutical and cosmetic fields
PT938302E (en) AQUOSA LIQUID COMPOSITION OF AGRADAVEL FLAVOR OF A BITTER TASTE DRUG
BR0115109A (en) Therapeutic agents and methods of their use for angiogenesis modulation
KR970064617A (en) Periodontal disease prevention and treatment composition
PT1102586E (en) USE OF GINKGO BILOBA EXTRACTS FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF AMIOTROPHIC LATERAL SCLEROSIS
EP0354554A3 (en) Anti-irritant and desensitizing compositions and methods of their use
DE69812100D1 (en) MEDICINAL PRODUCT CONTAINING ADENOSINE
KR960040370A (en) Alcohol Disorder Prevention and Treatment Composition
WO2001074365A3 (en) An efficacious dosage regimen of galantamine that reduces side effects
AU7286194A (en) Pharmaceutical composition for prophylaxis and treatment of premature ejaculation
Gutierrez et al. Pharmacokinetic comparison of oral solution and tablet formulations of citalopram: a single-dose, randomized, crossover study
KR930001926A (en) Pharmaceutical composition for the treatment of mental and neurological disorders
Tighilet et al. Pharmacological activity of the Ginkgo biloba extract (EGb 761) on equilibrium function recovery in the unilateral vestibular neurectomized cat
ATE233085T1 (en) MEDICINAL PRODUCTS FOR TOPICAL USE
KR960040369A (en) Alcohol Disorder Prevention and Treatment Composition
Luciano et al. Herbal treatment of epilepsy: phytotherapy
KR970073595A (en) Composition for the prevention and treatment of alcoholic disorders
Gottschalk Affective and cognitive problems with the benzodiazepines
BR0113101A (en) Use of a lipase inhibitor and oral process and medicament for treating, reducing or preventing functional dyspepsia
Qureshi et al. Effect of Alpinia galanga treatment on cytological and biochemical changes induced by cyclophosphamide in mice
Schouten FDA approves 2 new protease inhibitors: ritonavir (Norvir) and Crixivan (Indinavir sulfate). Food and Drug Administration
Ashar et al. Clinical trials for herbal extracts
O'Hair et al. Evaluation of short-term treatment with 30 mg of quazepam in insomniac outpatients
AU3478600A (en) Treatment of autoimmune diseases with american ginseng extract

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application